A proof-of-concept open-label clinical trial of spleen tyrosine kinase antagonism using fostamatinib in moderate-to-severe hidradenitis suppurativa
R Jepsen, C Edwards, A Flora, E Kozera… - Journal of the American …, 2023 - Elsevier
Background Hidradenitis suppurativa (HS) is an autoinflammatory disorder of keratinization
with a prominence of B cells and plasma cells. Fostamatinib is a spleen tyrosine kinase
inhibitor targeting B cells and plasma cells. Objectives To assess the safety, tolerability, and
clinical response at week 4 and week 12 of fostamatinib in moderate-to-severe HS. Methods
Twenty participants were administered fostamatinib 100 mg twice a day for 4 weeks,
escalating to 150 mg twice a day thereafter until week 12. Participants were assessed for …
with a prominence of B cells and plasma cells. Fostamatinib is a spleen tyrosine kinase
inhibitor targeting B cells and plasma cells. Objectives To assess the safety, tolerability, and
clinical response at week 4 and week 12 of fostamatinib in moderate-to-severe HS. Methods
Twenty participants were administered fostamatinib 100 mg twice a day for 4 weeks,
escalating to 150 mg twice a day thereafter until week 12. Participants were assessed for …
